Newsletter - November 2013


Kit Temperature During Cord Blood Shipments

Frances Verter, PhD

Any temperature extremes that would threaten the life of a child or a pet - being left in a parked car for more than a few minutes, traveling in the cargo hold of an airplane, etc. - also kills cord blood stem cells. The key to shipping fresh cord blood to the laboratory with maximum cell survival is to keep the temperature stable inside the shipping kit. But this simple requirement can be very challenging to implement.

Research has shown that blood-forming stem cells lose their viability when exposed to temperature extremes, either too hot or too cold (1-6). Based on this well established knowledge, regulatory authorities have always recommended that fresh cord blood be maintained at temperatures between 4 and 30 degrees Celsius during transport (7-9).

When cord blood is collected from a birth and must be shipped across countries or even oceans to reach the laboratory, there are numerous opportunities for temperature excursions. What type of vehicle is used to transport the cord blood to the airport, and where in the vehicle is the cord blood held? How long does the cord blood wait to board a plane, and where does it wait? Where does the cord blood travel in the plane? Finally, on the receiving end, how is the cord blood off-loaded from the plane and delivered to the laboratory?

Once upon a time, before the devastating events of Sept. 11, 2001 ("9/11"), the Parent's Guide to Cord Blood used to advise parents to hire a medical courier to carry their baby's cord blood with a "secure chain of custody". Those couriers would insure that cord blood was hand-carried from the inside of a temperature-controlled vehicle into the passenger compartment of an airplane, so that the shipping kit was always in a temperature-controlled environment.

In the post-9/11 world, airports have drastically increased their security, and medical transport procedures have had to adapt to this new reality. It is no longer possible for parents to hire a medical courier. Now couriers only work on contracts for companies that have been approved by national transportation authorities. Hence, the only way for parents to ship cord blood with a courier is to hire a cord blood bank that has a contract with a courier. Even so, the couriers no longer have the freedom to walk cord blood onto a boarding airplane. The cord blood must be delivered to the boarding ramp agents, who will load it on the plane. If the flight is delayed or cancelled, it is the ramp agents and not the courier who have discretion over where the cord blood package is held.

Under today's circumstances, it is more important than ever that the collection kits used to ship cord blood must have good temperature stability, because it is possible that the life of the blood cells will depend on the kit insulation for hours at a time. More insulation is always better, and more insulation usually means bigger kits.

In the United States, there are two very different scenarios in which parents ship cord blood. One is if the parents are donating the cord blood to a public bank that accepts donations by mail. Figure 1 displays the shipping kits used by mail-in donation programs. To keep costs down, these programs ship cord blood with FedEx, a transport service that provides no temperature guarantee whatsoever. Consequently, it is imperative that the shipping kits used by public banks must have enough insulation to maintain their internal temperature for the full 48 hour time window allowed for transport to a public bank. These kits are big square boxes that are so sturdy they can be sterilized and reused multiple times.

The more common scenario is one where parents have hired a private company to store their baby's cord blood for the family, and they receive a kit for collection and shipping that is more compact. Figure 2 displays the kits used by some of the family banks in the United States (each photo links to the bank web site). They are usually 9 to 14 inches wide but may only be 2.5 to 3 inches deep. Most of these kits represent a compromise: Most have less temperature stability than public bank kits, but they are intended to be carried by courier transport.

This leads to the question of how kit temperature stability is measured. Ideally, any claims that a cord blood bank makes for their shipping kit should be based upon standardized testing by an independent third party. The vast majority of claims that US family banks currently make for the temperature stability of their shipping kits are based upon their own validation tests (10-11). Instead, the banks should have a third party test their kits. Examples of standards agencies that certify and accredit package performance testing are International Safe Transit Association (ISTA) and International Air Transport Association (IATA).

If the temperature inside a cord blood shipping kit exceeded suggested limits during transit, is there any way to know? In fact yes, there is: if the kit contains a temperature logger or simply an out-of-range temperature detector, there will be a record. While temperature loggers are routinely used by family banks in the EU and Canada, very few family banks in the US market have temperature sensors in their kits. However, the 5th edition FACT accreditation standards issued in July 2013 (12) require family bank kits to measure whether the temperature has gone out of range.

To conclude, the Parent's Guide to Cord Blood recommends that parents who are selecting a family cord blood bank ask the following questions about their kits:

visual reminder of red shipping box 1. Ask the bank if their contract includes courier transport, and check that the transport company they name actually provides medical courier service.

visual reminder of red shipping box 2. Ask the bank if their shipping kit was tested by an independent third party.

visual reminder of red shipping box 3. Ask the bank how their shipping kit performs under standardized testing protocols for summer and winter.

visual reminder of red shipping box 4. Ask the bank if their kit contains a method to monitor the temperature once the cord blood is placed in the kit for shipment.

The more parents that ask these questions and demand reassuring answers, the more pressure there will be on US family banks to uniformly adopt high quality practices for cord blood transport.

Dr. Verter acknowledges invaluable assistance with the research behind this article from Greg Davis of First International Courier Systems, Richard Jennings of FamilyCord, Dr. Linda Kelley of Cryo-Cell International, and Dr. Ed Guindi of CORD:USE.

Figure 1: Collection kits for cord blood public donation

MDAnderson cord blood bank
MD Anderson cord blood bank
Carolinas cord blood bank
Carolinas cord blood bank

Figure 2: Collection kits from family cord blood banks


CORD:USE the only kit made of vacuum insulated panels

LifebankUSA showing temperature sensor
ViaCord showing instructions
Cord Blood Registry
Cord Blood Registry unique clamshell folding box
CReATe of Canada


  1. Yamaguchi M, Fujihara M, Wakamoto S, Sakai H, Takeoka S, Tsuchida E, Hamada H, Azuma H, Ikeda H (2009) Biocompatibility study of hemoglobin vesicles, cellular-type artificial oxygen carriers, with human umbilical cord hematopoietic stem/progenitor cells using an in vitro expansion system. ASAIO J. 55(3):200-205.
  2. Wierenga, PK, Setroikomo, R, Kamps, G, Kampinga, HH and Vellenga, E (2003) Differences in heat sensitivity between normal and acute myeloid leukemic stem cells: feasibility of hyperthermic purging of leukemic cells from autologous stem cell grafts. Exp Hematology 31(5):421-7.
  3. Wierenga, PK, Brenner, MK and Konings, AWT (1998) Enhanced selectivity of hyperthermic purging of human progenitor cells using Goralatide, an inhibitor of cell cycle progression. Bone Marrow Transplantation 21:73-78.
  4. Symonds, RP, Wheldon, TE , Clarke, B and Bailey, G (1981) A comparison of the response to hyperthermia of murine haemopoietic stem cells (CFU-S) and L1210 leukaemia cells: enhanced killing of leukaemic cells in the presence of normal marrow cells. Br. J. Cancer 44:682-691.
  5. Elkon, D, Sabio, H, Pinizzotto, M, Sigurdsson, M and Baker, DG (1984) Effect of hyperthermia on murine myeloid precursors. Cancer 54(9):1973-1976.
  6. Elkon, D, Sabio, H, McGrath, E and Baker, D. (1981) Temperature dependent inhibition of murine granulocyte-monocyte precursors. Cancer Research 41:1812-1816.
  7. Food and Drug Administration. Guidance for industry: minimally manipulated unrelated allogeneic placental/umbilical cord blood intended for hematopoietic reconstitution for specified indications. Rockville, MD: CBER Office of Communication, Outreach, and Development; 2009.
  8. AABB Cellular Therapy Standards 6th edition effective July 1, 2013.
  9. Foundation for the Accreditation of Cellular Therapy FACT Cord Blood Bank Standards 5th edition effective July 1, 2013.
  10. St. Jour, L, Popp, D, Robbins, P and Kelley, L (2013) Development of a Cost-effective, Single-use Container to Maximize Protection from High Temperature for Transportation of Fresh Umbilical Cord Blood. poster at 11th International Cord Blood Symposium, San Francisco, June 2013.
  11. Wolfson, RN (2013) Ob.Gyn. News, Supplement, July 2013 issue
  12. From FACT: "The standards that address transportation of cord blood units from the collection site to the processing facility are the C7 standards in the 5th edition NetCord-FACT Standards. C7.5 specifically deals with the temperature, however, it does not state the temperature that must be maintained but instead requires that the appropriate temperature range be determined by the bank and specified in the appropriate SOPs (see also C6.7.2- storage temperature). Standard C7.5.2 requires that the temperature inside the outer container be continuously monitored."

Treating Pelvic Organ Prolapse with Stem Cell Based Therapies

Caroline E. Gargett, PhD

Caroline E. Gargett, PhD, The Ritchie Centre, Monash Institute of Medical Research, Melbourne, Australia

You might be asking "Just what is pelvic organ prolapse, or POP?" POP is when the bladder, and/or bowel, and/or uterus herniates into the vagina. Twenty five percent of all women have one or more symptoms of POP: urinary or bowel incontinence and sexual dysfunction - this is why it is a taboo subject - the symptoms are so embarrassing.

POP mainly results from pregnancy and injury associated with vaginal birth, particularly after prolonged second stage labour or the use of forceps. Delivering a large baby and having an episiotomy can also cause POP. POP is exacerbated by obesity, ageing, chronic coughing, heavy lifting and straining associated with constipation. Women who deliver their first baby over the age of 30 tend to have more severe POP.

Conservative treatment involves pelvic floor exercises, but in many cases surgical reconstruction (repair) operations are required. In fact 11-19% of women will have at least one operation for POP and 15-29% of these women will have multiple surgeries. Synthetic and biological mesh materials were rapidly introduced to provide extra support to the prolapsed pelvic tissues and to improve surgical outcomes.

While the use of mesh improved symptoms for many women, they have introduced another set of problems, often requiring their surgical removal if this is possible. The FDA has posted two warnings on the use of polypropylene mesh in vaginal surgery for POP, which has alerted clinicians to high rates (about 10%) of adverse events associated with their use. This has led to withdrawal from the market of several widely used brands of vaginal mesh, and looming class-action litigation. There is now a real risk that treatment options will become limited and ineffective again for large numbers of women.

We are investigating a potential stem cell-based therapy for POP using a tissue engineering approach rather than mesh alone. Our reasoning is that stem cells, particularly mesenchymal stem cells (MSCs), might assist in repairing the vaginal wall tissues that are damaged from childbirth injury.

The source of the MSCs for this tissue engineering approach is novel. We have discovered that the endometrial lining of the uterus which is shed and regenerates each month during menstruation contains a population of MSCs. These are easily collected from women via a biopsy in the doctor's office, without the need for any form of anaesthesia, in contrast to the collection procedures for bone marrow or fat sources of MSC stem cells.

Our techniques to purify these endometrial MSCs use magnetic beads and special markers, and we are currently working out protocols for growing them in culture to produce large numbers of cells under Good Manufacturing Practice (GMP) conditions. Our goal is to develop a stem cell-based therapy where women can use their own endometrial MSCs. The cells will be embedded in new, more patient-friendly, mesh materials that we have also been developing, that actually match the mechanical properties of human vaginal tissue.

We have demonstrated the proof-of-principle for this approach in an animal model that repaired wounds in the skin of rats. Our study showed that a tissue engineering construct comprising our new mesh and human endometrial MSCs significantly improved the mechanical properties of the mesh after a prolonged period of time (3 months). The endometrial MSCs appeared to exert their effect right from the beginning, by inducing the formation of new blood vessels around the implanted mesh, and altering the response of the body's immune system by promoting a wound healing effect rather than chronic inflammation. This in turn resulted in the laying down of new healthy collagen fibres through the mesh, in contrast to the mesh without cells where a thick scarring type of collagen formed.

The ability of the new mesh to grow healthy collagen fibres is important because it allows the new mesh to be more elastic and distensible, which addresses the key problem of currently used meshes and is the goal of our cell-based therapy.

Despite the millions of women in need of better treatment for POP, our ultimate goal is to prevent POP. We believe that if women are treated with their own MSCs soon after childbirth, using a less invasive introduction of cells, then their bodies will repair damaged pelvic floor muscles, vaginal walls, and ligaments years before POP has time to become severe enough to require reconstructive surgery. Clearly there is much research required before this goal can be achieved and the hidden disease burden of POP can be prevented.

Associate Professor Caroline Gargett is a Senior Research Fellow of the National Health and Medical Research Council of Australia, and Deputy Director of the Ritchie Centre at Monash Institute of Medical Research, Melbourne Australia, where she heads Women's Health. She is also a member of Monash University's Department of Obstetrics and Gynaecology. Dr Gargett obtained her PhD in 1997 and became an independent researcher in 2004 when she discovered adult stem cells in the lining of the uterus (endometrium). She leads a research group of 8-12 staff and students and her research focuses on examining the role of endometrial stem cells in endometriosis. She is also developing novel approaches for treating pelvic organ prolapse using endometrial stem cells and new materials in collaboration with Materials Scientists and Tissue Engineers from CSIRO, Australia's leading Scientific and Industrial Research Organisation. She is President of the Australasian Society for Stem Cell Research and is on the Editorial Boards of Reproductive Sciences, Fertility and Sterility and Biology of Reproduction.